Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 15 PAGES: 56

More Info
									   Adrenocortical Carcinoma (Adrenal Cortex Cancer) –
                Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1927IDB
                                                                                              Publication Date: April 2012




Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H1 2012                   GMDHC1927IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review,
H1 2012



Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview........................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) .......................................................... 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Development by Companies ........................................... 10
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics under Investigation by Universities/Institutes ............................ 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Products under Development by Companies ......................... 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Products under Investigation by Universities/Institutes .......... 17
Companies Involved in Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics Development........................................ 18
    OSI Pharmaceuticals, Inc. ........................................................................................................................................................... 18
    Pfizer Inc...................................................................................................................................................................................... 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment ........................................................................... 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Combination Products ........................................................................................................................................ 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    Inlyta - Drug Profile ...................................................................................................................................................................... 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    OSI-906 - Drug Profile ................................................................................................................................................................. 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Seneca Valley Virus-001 - Drug Profile ....................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Mitotane - Drug Profile ................................................................................................................................................................. 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31



Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review, H1 2012                                                                        GMDHC1927IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Review,
H1 2012



        R&D Progress ......................................................................................................................................................................... 31
    Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile .................................................................................................... 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 33
    Streptozocin + Mitotane - Drug Profile ......................................................................................................................................... 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    G-CSF + Pegfilgrastim + Cisplatin + Doxorubicin + Etoposide + Mitotane - Drug Profile ............................................................ 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 37
    Doxorubicin + Vincristine + Etoposide + Mitotane - Drug Profile ................................................................................................. 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 39
    Mitotane + Cixutumumab - Drug Profile....................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Etoposide + Doxorubicin + Cisplatin + Mitotane - Drug Profile .................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Streptozotocin + Mitotane - Drug Profile ...................................................................................................................................... 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Sunitinib - Drug Profile ................................................................................................................................................................. 44
        Product Description................................................................................................................................................................. 44
        Mechan
								
To top